Catalyst Pharmaceuticals Inc (CPRX) News & EventsCPRXCatalyst Pharmaceuticals Inc

Solaris Energy to Replace Catalyst Pharmaceuticals in S&P SmallCap 600

Solaris Energy Infrastructure (SEI) will replace Catalyst Pharmaceuticals (CPRX) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, July 15. Angelini Pharma S.p.A. is acquiring Catalyst Pharmaceuticals in a deal expected to close soon, pending final closing conditions.

H.C. Wainwright Downgrades Catalyst Pharmaceuticals to Neutral with $31.50 Price Target

H.C. Wainwright downgraded Catalyst Pharmaceuticals to Neutral from Buy with a $31.50 price target after the company agreed to be acquired by Angelini Pharma at a price of $31.50 per share in cash. The firm does not expect an additional bidder to emerge.

FIRDAPSE Q1 Revenue Reaches $98.9 Million

Reports Q1 revenue $149.4M, consensus $148.18M. FIRDAPSE Q1 2026 product revenue, net was $98.9 million, an 18.1% year-over-year increase, primarily driven by increases in sales volumes. AGAMREE Q1 2026 product revenue, net was $36.7 million, compared to product revenue, net of $22.0 million in Q1 2025. The results underscore continued sales volume growth and increasing prescriber engagement. FYCOMPA Q1 2026 product revenue, net was $13.8 million, a 61.3% year-over-year decrease following loss of exclusivity in 2025.